Editorial: autoimmunity to vimentin and lupus nephritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Reciprocal regulation of SIRT1 and AMPK by Ginsenoside compound K impedes the conversion from plasma cells to mitigate for podocyte injury in MRL/Journal of ginseng research · 2024
   Article
2. Alpha-1-antitrypsin in serum exosomes and pericardial fluid exosomes is associated with severity of rheumatic heart disease.Molecular and cellular biochemistry · 2023
   Article
3. The expression of EBV-encoded LMP1 in young patients with lupus nephritis.International journal of clinical and experimental medicine · 2015
   Article

Corrections and comments

• Comment on
  Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis.2014

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as